Consumer Health Cancer / Oncology
Gilead and Kite Oncology, announced that two poster presentations, covering results from two of the largest real-world analyses, will be presented during t...
November 03, 2023 | News
Bristol Myers Squibb to Acquire Mirati for $58.00 Per Share, Representing $4.8 Billion Equity Value and Up to $5.8 Billion Including the Contingent Value R...
October 10, 2023 | News
On September 28, 2023, Akeso (9926.HK) announced that its subsidiary, Akeso Pharma, will collaborate with RemeGen (Yantai) Co., Ltd. (688331.SH/0...
October 02, 2023 | News
On September 23, 2023, oncologists and experts from more than 60 clinical research centers across the country gathered in Guangzhou to ...
September 25, 2023 | News
Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading commercial-stage innovative, global biopharmaceutical company dedicated to disco...
September 22, 2023 | News
"We are excited to work with NCCS to uncover the unique molecular genomic composition of cancers prevalent in Asia by providing our DNBSEQ-G400 s...
September 18, 2023 | News
Bristol Myers Squibb and Samsung Biologics have an existing manufacturing agreement for a commercial antibody cancer drug and have expanded the s...
September 18, 2023 | News
Paige, a global leader in end-to-end digital pathology solutions and clinical AI, developed the first Large Foundation Model using over one billion images ...
September 08, 2023 | News
In this exclusive interview with Dr. Jerome Boyd-Kirkup, Chief Scientific Officer of Hummingbird Bioscience, BioPharma APAC delve into the recently i...
September 06, 2023 | News
As a reputable boutique CRO with a strong track record of delivering high-quality, expedited clinical trials in the Asia-Pacific, HiRO's acquisit...
September 01, 2023 | News
SK10, the first Bacteroides fragilis-based live biotherapeutic product (LBP) obtained FDA IND approval, is also the first LBP of Next-generation probi...
August 28, 2023 | News
Ebdarokimab is Akeso's 6th self-developed innovative drug that has been successfully approved for marketing/NDA submitted, the first patented domestic inno...
August 25, 2023 | News
IPAX-2 (ClinicalTrials.gov Identifier: NCT05450744) is a Phase I dose escalation study to confirm safety profile of TLX101 in combination with externa...
August 08, 2023 | News
HaemaLogiX and Peter MacCallum Cancer Centre have entered a collaboration agreement to develop and conduct the first Phase I human trial of HaemaLogiX's ...
July 26, 2023 | News
Most Read
Bio Jobs
News